MediPharm Labs Corp. has announced an update regarding the sale of its Napanee facility to Kensana Health Inc.
The transaction, valued at $5.5 million in cash, involves the sale of all equity interests in MediPharm’s subsidiary, ABcann Medicinals. The deal is now set to close by January 31, 2025, following an extension of the original closing date.
MediPharm and Kensana Health are continuing to work toward completing the sale, with the transaction still subject to standard closing conditions and necessary approvals. Despite the pending sale, operations at the Napanee facility continue without disruption.
For more information, MediPharm Labs referred to its press release from December 17, 2024.
Written by Emily Chatwood
